INTRODUCTION: Common variable immunodeficiency is a heterogeneous antibody deficiency syndrome with autoimmune and inflammatory complications in a significant proportion of patients. The study was designed to evaluate the role of T regulatory (Treg) cells in common variable immunodeficiency (CVID) patients with autoimmunity. METHODS: The number and frequency of Treg cells (CD4(+), CD25(hi), Foxp3(+)) were evaluated in patients and controls, and Foxp3 expression in different subgroups of CVID patients with common clinical manifestations was compared. RESULTS: CVID patients had significantly fewer Treg cells than controls, and low frequency of Treg cells was associated with expansion of CD21(lo) B cells in patients. Patients with autoimmunity had significantly reduced frequency but normal numbers of regulatory T cells, whilst patients with splenomegaly had significant reduction in frequency and number of regulatory T cells. CONCLUSION: Foxp3 is useful on its own or as an adjunct to classify CVID patients although the possibility of reduction in Treg cells as a secondary phenomenon cannot be excluded.
INTRODUCTION: Common variable immunodeficiency is a heterogeneous antibody deficiency syndrome with autoimmune and inflammatory complications in a significant proportion of patients. The study was designed to evaluate the role of T regulatory (Treg) cells in common variable immunodeficiency (CVID) patients with autoimmunity. METHODS: The number and frequency of Treg cells (CD4(+), CD25(hi), Foxp3(+)) were evaluated in patients and controls, and Foxp3 expression in different subgroups of CVIDpatients with common clinical manifestations was compared. RESULTS:CVIDpatients had significantly fewer Treg cells than controls, and low frequency of Treg cells was associated with expansion of CD21(lo) B cells in patients. Patients with autoimmunity had significantly reduced frequency but normal numbers of regulatory T cells, whilst patients with splenomegaly had significant reduction in frequency and number of regulatory T cells. CONCLUSION:Foxp3 is useful on its own or as an adjunct to classify CVIDpatients although the possibility of reduction in Treg cells as a secondary phenomenon cannot be excluded.
Authors: Mirzokhid Rakhmanov; Baerbel Keller; Sylvia Gutenberger; Christian Foerster; Manfred Hoenig; Gertjan Driessen; Mirjam van der Burg; Jacques J van Dongen; Elisabeth Wiech; Marcella Visentini; Isabella Quinti; Antje Prasse; Nadine Voelxen; Ulrich Salzer; Sigune Goldacker; Paul Fisch; Hermann Eibel; Klaus Schwarz; Hans-Hartmut Peter; Klaus Warnatz Journal: Proc Natl Acad Sci U S A Date: 2009-07-29 Impact factor: 11.205
Authors: B Piqueras; C Lavenu-Bombled; L Galicier; F Bergeron-van der Cruyssen; L Mouthon; S Chevret; P Debré; C Schmitt; E Oksenhendler Journal: J Clin Immunol Date: 2003-09 Impact factor: 8.317
Authors: R S Wildin; F Ramsdell; J Peake; F Faravelli; J L Casanova; N Buist; E Levy-Lahad; M Mazzella; O Goulet; L Perroni; F D Bricarelli; G Byrne; M McEuen; S Proll; M Appleby; M E Brunkow Journal: Nat Genet Date: 2001-01 Impact factor: 38.330
Authors: Grace P Yu; David Chiang; Steven J Song; Elisabeth G Hoyte; Jennifer Huang; Christopher Vanishsarn; Kari C Nadeau Journal: Clin Immunol Date: 2009-01-22 Impact factor: 3.969
Authors: S Jolles; E Carne; M Brouns; T El-Shanawany; P Williams; C Marshall; P Fielding Journal: Clin Exp Immunol Date: 2016-11-28 Impact factor: 4.330
Authors: Swati Phalke; Katja Aviszus; Kira Rubtsova; Anatoly Rubtsov; Briana Barkes; Linda Powers; Brenda Warner; James L Crooks; John W Kappler; Evans R Fernández-Pérez; Lisa A Maier; Nabeel Hamzeh; Philippa Marrack Journal: Am J Respir Crit Care Med Date: 2020-10-01 Impact factor: 21.405
Authors: E A L Bateman; L Ayers; R Sadler; M Lucas; C Roberts; A Woods; K Packwood; J Burden; D Harrison; N Kaenzig; M Lee; H M Chapel; B L Ferry Journal: Clin Exp Immunol Date: 2012-11 Impact factor: 4.330